What is Iovance Biotherapeutics, Inc. (IOVA) stock price today?

Iovance Biotherapeutics, Inc. (IOVA) is currently trading at $14.62, up 9.84% today.

What is IOVA P/E ratio?

Iovance Biotherapeutics, Inc.'s P/E ratio is -20.16. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IOVA return on equity (ROE)?

Iovance Biotherapeutics, Inc.'s return on equity (ROE) is -40.51%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Iovance Biotherapeutics, Inc.'s market cap?

Iovance Biotherapeutics, Inc. has a market capitalization of $6.53B.

NASDAQ · Biotechnology

Iovance Biotherapeutics, Inc. (IOVA) Stock

$14.62 +9.84% NASDAQ: IOVA Healthcare

Valuation

Metric	Value
Price	$14.62
Market Cap	$6.53B
P/E Ratio	-20.16
P/B Ratio	8.63
P/S Ratio	19.39
EPS (TTM)	$-0.28
52-Week High	$15.30
52-Week Low	$1.76
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-40.51%
ROA	-31.62%
ROCE	-37.26%
Gross Margin	1.15%
Operating Margin	-1.27%
Net Margin	-89.09%
Debt/Equity	0.06
Current Ratio	3.21

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$1.0M	$164.0M	$264.0M
Operating Profit	$-343.0M	$-399.0M	$-461.0M	$-395.0M	$-403.0M
Net Profit	$-342.0M	$-396.0M	$-444.0M	$-372.0M	$-391.0M
EPS	$-2.23	$-2.49	$-1.89	$-1.28	$-1.09
Op Margin	—	—	-38735.0%	-240.9%	-153.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$777.0M	$664.0M	$780.0M	$910.0M	$913.0M
Total Liabilities	$156.0M	$164.0M	$196.0M	$200.0M	$215.0M
Cash	$78.0M	$232.0M	$115.0M	$116.0M	$163.0M
Borrowings	$72.0M	$85.0M	$76.0M	$58.0M	$48.0M

Latest News

Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note Insider Monkey · Jul 9, 2026 This Stock Is Up 74% This Year: Is It Too Late to Buy? Motley Fool · Jul 8, 2026 Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? Motley Fool · Jul 4, 2026 Iovance (IOVA) Surges 9.4% on Regulatory Nod Insider Monkey · Jun 24, 2026 Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? Motley Fool · Jun 23, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-228.0M	$-293.0M	$-362.0M	$-353.0M	$-302.0M
Investing Cash Flow	$-37.0M	$236.0M	$-178.0M	$-107.0M	$14.0M
Financing Cash Flow	$35.0M	$1.0M	$0	$-7.0M	$-7.0M
Net Cash Flow	$11.0M	$154.0M	$-57.0M	$-59.0M	$47.0M
Free Cash Flow	$-266.0M	$-313.0M	$-384.0M	$-364.0M	$-336.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.33
EV / EBITDA	-23.73
FCF Yield	-4.70%
Quick Ratio	3.82
Interest Coverage	0.00
Return 1Y	241.32%
Return 3Y	34.97%
Return 5Y	-77.51%

Ownership

Insiders Held0.34%

Institutions Held67.72%

Institutions Float Held67.95%

Institutional Holder	Shares	Report Date
Blackrock Inc.	31,080,505	2026-03-31
MHR Fund Management, LLC	28,967,103	2026-03-31
State Street Corporation	17,448,108	2026-03-31
Vanguard Capital Management LLC	16,617,737	2026-03-31
Two Sigma Investments, LP	13,687,433	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALXOALX Oncology Holdings Inc.	$1.25	+5.93%	-1.08	$168.20M	0.00%
BNTXBioNTech SE	$90.07	-1.55%	-15.45	$22.78B	0.00%
FATEFate Therapeutics, Inc.	$2.18	+2.35%	-2.21	$254.10M	0.00%
GMABGenmab A/S	$29.00	-2.62%	21.45	$17.80B	0.00%
IBRXImmunityBio, Inc.	$10.51	+6.05%	-10.01	$11.01B	0.00%

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is led by CEO Frederick G. Vogt, publicly traded since 2010.

Iovance Biotherapeutics, Inc. (IOVA) stock trades at $14.62 with a market capitalization of $6.53B. The stock is valued at a price-to-earnings (P/E) ratio of -20.16, price-to-book of 8.63, price-to-sales of 19.39. Over the past 52 weeks the stock has ranged between $1.76 and $15.30, and currently trades 4.4% below its 52-week high.

On profitability, Iovance Biotherapeutics, Inc. generates a return on equity (ROE) of -40.51%, return on capital employed of -37.26%, an operating margin of -1.27%, a net profit margin of -89.09%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides